论文部分内容阅读
目的通过检测乳腺癌组织中肺癌肿瘤抑制物1(TSLC1)蛋白的表达及临床病理学意义,探讨其在乳腺癌发生、发展过程中的作用。方法应用免疫组化(SP法)检测50例乳腺癌标本中TSLC1蛋白表达及癌旁正常乳腺组织中TSLC1蛋白的表达情况,观察其与乳腺癌患者临床病理学参数之间的关系。结果TSLC1蛋白在乳腺癌组织中的阳性表达率为40%(20/50),而在癌旁正常乳腺组织中的阳性表达率为92%(46/50),乳腺癌组织中的阳性表达率显著低于癌旁正常乳腺组织,两者相比差异有统计学意义(P<0.01)。TSLC1蛋白在乳腺癌(非浸润性癌)中的阳性表达率为71.4%(5/7),而在乳腺癌(浸润性癌)中的阳性表达率为34.9%(15/43),阳性表达率随乳腺癌侵袭范围的扩大而降低,但癌组织两型间差异无统计学意义(P>0.05)。乳腺癌淋巴结有癌转移组中TSLC1蛋白的阳性表达率为50%(11/22),而淋巴结无癌转移组中的阳性表达率为89%(25/28),淋巴结有癌转移组中的阳性表达率明显低于淋巴结无癌转移组,两者相比差异有统计学意义(P<0.01)。但其表达与肿瘤大小、年龄及临床分期无关。结论乳腺癌组织中有明显的TSLC1蛋白的表达缺失,TSLC1蛋白阳性表达率随乳腺癌侵袭范围(非浸润性癌-浸润性癌)的扩大而降低,提示TSLC1蛋白表达缺失与乳腺癌的发生、发展有关。
Objective To investigate the expression of TSLC1 in breast cancer and its clinicopathological significance, and to explore the role of TSLC1 in the development and progression of breast cancer. Methods The expression of TSLC1 protein in 50 cases of breast cancer specimens and the expression of TSLC1 protein in adjacent normal breast tissues were detected by immunohistochemistry (SP method), and the relationship between the expression of TSLC1 protein and the clinicopathological parameters of breast cancer patients was observed. Results The positive rate of TSLC1 protein in breast cancer was 40% (20/50), while it was 92% (46/50) in normal breast tissues. The positive rate of TSLC1 protein in breast cancer Which was significantly lower than that in adjacent normal breast tissues (P <0.01). The positive rate of TSLC1 protein in breast cancer (non-invasive carcinoma) was 71.4% (5/7), while it was 34.9% (15/43) in breast cancer (invasive carcinoma) The rate decreased with the expansion of the invasion of breast cancer, but there was no significant difference between the two types of cancer (P> 0.05). The positive rate of TSLC1 protein in breast cancer lymph node metastasis group was 50% (11/22), while the positive rate of TSLC1 protein in lymph node metastasis group was 89% (25/28) The positive expression rate was significantly lower than that without lymph node metastasis, the difference was statistically significant (P <0.01). However, its expression was not related to tumor size, age and clinical stage. Conclusion The expression of TSLC1 protein is significantly decreased in breast cancer tissues. The positive expression rate of TSLC1 protein is decreased with the expansion of breast cancer (non-invasive carcinoma-invasive carcinoma), suggesting that the loss of TSLC1 protein and the occurrence of breast cancer, Development related.